Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.57 USD | +0.78% | -1.63% | -14.26% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
Financials (USD)
Sales 2024 * | 1.88B | Sales 2025 * | 2.06B | Capitalization | 5.99B |
---|---|---|---|---|---|
Net income 2024 * | 342M | Net income 2025 * | 444M | EV / Sales 2024 * | 2.59 x |
Net cash position 2024 * | 1.12B | Net cash position 2025 * | 1.67B | EV / Sales 2025 * | 2.1 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
14
x | Employees | 1,310 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.83% |
Latest transcript on Exelixis, Inc.
1 day | +0.78% | ||
1 week | -1.63% | ||
Current month | -12.32% | ||
1 month | -13.24% | ||
3 months | -4.46% | ||
6 months | -5.12% | ||
Current year | -14.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 00-01-31 | |
Director of Finance/CFO | 56 | 15-07-14 | |
Amy Peterson
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 04-12-31 |
Director/Board Member | 68 | 04-01-31 | |
George Poste
BRD | Director/Board Member | 79 | 04-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.24% | 254 M€ | +13.10% | - | |
2.62% | 1 M€ | -0.95% | - | |
1.67% | 8 M€ | +4.90% | ||
1.59% | 2 M€ | 0.00% | ||
1.30% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 20.57 | +0.78% | 1,704,028 |
24-05-23 | 20.41 | -2.81% | 1,795,614 |
24-05-22 | 21 | -0.10% | 1,528,552 |
24-05-21 | 21.02 | -0.19% | 1,774,001 |
24-05-20 | 21.06 | +0.72% | 1,791,287 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.26% | 5.99B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- EXEL Stock